

PERSONAL INFORMATION

Imperia Nuzzolese



Gender **F** | Date of birth **24/06/1987** | Nationality **Italian**

TITLE

MD, Specialist in Medical Oncologist, Ordine BA 15341

EDUCATION AND TRAINING

11-12.02.2022	Master NIBIT of II level in Immuno-Oncology
Since 01/2021	Collaboration on a project at Head and Neck Oncology Unit, Medical Oncology, Istituto Nazionale Tumori, Milan, IT (prof. L. Licitra) working as referring physician at "head and neck department"
26-27.11.2020	Master NIBIT of I level in Immuno-Oncology
11.2015 – 11.2020	Residency: Department of Medical Oncology, Candiolo FPO IRCCS , University of Turin, Italy. Final mark 70/70 cum laude. Research Project: "Exploring the utility of attrition rate in prostate cancer"
29-30.11.2019	ESMO Preceptorship on Kidney Cancer. Case Report Presentation: A singular case of long-lasting response to Sorafenib
10-11.10.2019	Emergency US Provider , First level course SIUMB, Bologna, Maggiore Hospital
20-21.09.2019	BLSD and ALS provider course, Torino, Mauriziano Hospital
21-23.02.2019	Winter School on Prostate Cancer, SIUrO
03-05.03.2016	Winter School on Prostate Cancer, SIUrO

07/2006	High school diploma from the Liceo Classico Statale (gymnasium) "G. Zanardelli " , Altamura, Italy. Mark: 100/100
---------	--

PERSONAL SKILLS

First Language Italian

Languages	READING ABILITY		SPEAKING ABILITY		WRITING ABILITY
	Listening	Reading	Interaction	Oral Ability	
English	C1	C1	C1	C1	C1
French	A2	A2	A2	A2	A2

Communication skills

Good knowledge of the English language improved thanks to periods of study abroad in the context of competitive European study programs (Dublin, Bratislava).
Proficiency in the French language is at a basic level which is being improved.

Social skills

Excellent team spirit;
Ability to adapt to multicultural environments, free from prejudices of a social, ethnic, religious or cultural nature;
Good communication skills improved over the formative years.
Quickness in learning.

Technical skills and competences

- **Treatment and Management of Cancer Patients:** Clinical experience in managing inpatients and outpatients mainly with urological and testicular cancers even in multidisciplinary case discussions acquired during the training at the Department of Medical Oncology, IRCCS Candiolo FPO, University of Turin. Current Director: Prof. M. Aglietta, Since 2021, clinical experience in managing inpatients with head and neck tumours even in multidisciplinary case discussions acquired during a collaboration project at Head and Neck Oncology Unit, Medical Oncology, Istituto Nazionale Tumori, Milan, IT (prof. L. Licitra)
- **Treatment and Management of Prostate, Kidney, Bladder Cancer Patients enrolled in clinical trials:** skills and competences developed during the training at the Department of Medical Oncology, IRCCS Candiolo FPO, University of Turin. Current Director: Prof. M. Aglietta

- **Treatment and Management of Head and Neck Cancer Patients enrolled in clinical trials:** skills and competences developed during the clinical activity at the Department of Medical Oncology (OM3), Istituto Nazionale Tumori Milano, University of Milan. Current Director: prof. Lisa Francesca Licitra

- **Sub-investigator** of the following phase II/III Clinical Trials in patients affected by urological or head and neck cancers : B9991001, HERO-MVT-601-3201, Arches 9785-CL0335,, Aramis, LPS-CARD, IPI-549-02, MK 3475-052, 56021927PCR 3001, INCB 54828-201, RESORT, AVEO, INCB 54828-205, Cheiron, ATLAS PCR3003, ITT012-ELISA,7465-CL-031EV-301, XL184-313, EORTC 1559, KOTIP007, ISA 101B, SANCUSO trial, BO 42533, LEAP 010, INTERLINK 1, NISSO, BURAN, INCAGN 2385-203 etc.

- Contribution to a number of abstracts presented to different national and international oncology congresses

- **Personal Computer:** Good level of knowledge and use of the following programmes: Microsoft Word, Excel, Power Point, Explorer

Driving license B

MORE INFORMATION

Publications

1. Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials? Nuzzolese I, Montemurro F. Lancet Oncol 2020

2. Neoadjuvant or Adjuvant chemotherapy in early breast cancer? Montemurro F., Nuzzolese I., Ponzzone R. Expert Opinion on Phamacotherapy, 2020

3. Prospective evaluation of the cardiovascular safety profile of abiraterone acetate (AA) in mCRPC patients (pts), Prati V. et al. Future oncology, 2018

4. Long-lasting response with Lapatinib treatment: a case report , Milani A. et al. journals.aboutscience.eu., 2018

5. Cavalieri S, Filippini DM, Ottini A, Bergamini C, Resteghini C, Colombo E, Lombardo R, Nuzzolese I, Alfieri S, Licitra L, Locati LD. Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. *Explor Target Antitumor Ther.* 2021

 6. Cavalieri S, Nuzzolese I, Licitra L. Which future for de-intensified treatments in HPV-related oropharyngeal carcinoma? *Semin Oncol.* 2022 Oct

 7. Cavalieri S, Bossi P, Infante G, Miceli R, Iacovelli NA, Ivaldi E, Locati LD, Bergamini C, Resteghini C, Nuzzolese I, Alfieri S, Colombo E, Ingargiola R, Franceschini M, Calareso G, Licitra LF and Orlandi E. The interplay between age and viral status in nasopharyngeal and oropharyngeal carcinoma patients. *Cancers* 2022 Dec
 8. Cavalieri S, Nuzzolese I et al. Targeting Human Epidermal Growth Factor Receptor 2 (HER2) in Salivary Gland Carcinoma (submitted)
 9. Attrition rate in prostate cancer, Nuzzolese I., Di Maio M. et al. (in submission)
- Other: Promoter of AIFA 648/96 request for off label approval of Trastuzumab in salivary glands tumors with HER2 overexpression/amplification

The undersigned authorizes the processing of personal data under the law 675/96 and subsequent amendments of 2003.

Dr. Imperia Nuzzolese

--